Mingxi is the President of Apeiron Therapeutics. Dr. Li specializes in identifying and commercializing early-stage life science innovation. He started his career at Jiuding Capital, focusing on healthcare investments in China and led the investment in Zhejiang Chengyi Pharmaceutical (SH: 603811). Mingxi later joined Simcere Pharmaceutical Group managing its $US 200 million investment in life science companies globally. Mingxi graduated from Tsinghua University and received his Ph.D. degree in Biochemistry from the University of Illinois at Urbana-Champaign.